Medexus Pharmaceuticals Inc. (OTCMKTS:MEDXF) Short Interest Up 30.5% in April

Medexus Pharmaceuticals Inc. (OTCMKTS:MEDXF) was the target of a significant growth in short interest during the month of April. As of April 15th, there was short interest totalling 103,600 shares, a growth of 30.5% from the March 31st total of 79,400 shares. Based on an average daily volume of 42,900 shares, the days-to-cover ratio is currently 2.4 days.

Medexus Pharmaceuticals Stock Down 7.2 %

Medexus Pharmaceuticals stock traded down $0.10 during mid-day trading on Tuesday, reaching $1.35. The company’s stock had a trading volume of 1,100 shares, compared to its average volume of 19,269. Medexus Pharmaceuticals has a 12 month low of $0.84 and a 12 month high of $2.56. The business’s 50 day simple moving average is $1.22 and its 200 day simple moving average is $1.43.

About Medexus Pharmaceuticals

Medexus Pharmaceuticals Inc operates as a specialty pharmaceutical company in Canada and the United States. The company focuses on the therapeutic areas comprising oncology, hematology, rheumatology, auto-immune diseases, allergy, and dermatology. Its primary products are IXINITY, an intravenous recombinant factor IX therapeutic for use in patients 12 years of age or older with hemophilia B; Rasuvo and Metoject, a formulation of methotrexate designed to treat rheumatoid arthritis and other auto-immune diseases; Rupall, a prescription allergy medication; and Gleolan, an optical imaging agent indicated in patients with glioma as an adjunct for the visualization of malignant tissue during surgery.